Report Detail
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
- RnM3839043 |
- 28 November, 2019 |
- Global |
- 132 Pages |
- GlobalData |
- Medical Devices & Consumables
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
Summary
GlobalData's Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Liver Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
- 1.1 List of Tables 5
- 1.2 List of Figures 7
2 Introduction 8
- 2.1 Liver Cancer Diagnostic Tests Overview 8
3 Products under Development 9
- 3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
- 3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
- 3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
- 3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
- 3.5 Liver Cancer Diagnostic Tests - Ongoing Clinical Trials 13
4 Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies 14
- 4.1 Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 14
- 4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16
5 Liver Cancer Diagnostic Tests Companies and Product Overview 18
- 5.1 Abbott Diagnostics Company Overview 18
- 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
- 5.2 Abcodia Ltd Company Overview 23
- 5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
- 5.3 AXO Science SAS Company Overview 24
- 5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 24
- 5.4 BioMark Technologies Inc Company Overview 27
- 5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 27
- 5.5 Bioprognos SL Company Overview 28
- 5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 28
- 5.6 China Sky One Medical Inc Company Overview 29
- 5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29
- 5.7 Digna Biotech SL Company Overview 30
- 5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 30
- 5.8 Exact Sciences Corp Company Overview 32
- 5.8.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 32
- 5.9 Fujirebio Diagnostics Inc Company Overview 34
- 5.9.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 34
- 5.10 German Cancer Research Center Company Overview 35
- 5.10.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 35
- 5.11 Glycotest Inc Company Overview 36
- 5.11.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 36
- 5.12 ImCare Biotech LLC Company Overview 39
- 5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 39
- 5.13 Imperial College London Company Overview 40
- 5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
- 5.14 IntegraGen SA Company Overview 41
- 5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 41
- 5.15 Matrix-Bio Inc Company Overview 42
- 5.15.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 42
- 5.16 MDNA Life Sciences Inc Company Overview 44
- 5.16.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 44
- 5.17 Medical University of South Carolina Company Overview 45
- 5.17.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 45
- 5.18 Medical University of Vienna Company Overview 46
- 5.18.1 Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 46
- 5.19 Memorial Sloan Kettering Cancer Center Company Overview 47
- 5.19.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 47
- 5.20 NanoString Technologies Inc Company Overview 48
- 5.20.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 48
- 5.21 Numares AG Company Overview 49
- 5.21.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 49
- 5.22 Oncimmune (USA) LLC Company Overview 50
- 5.22.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 50
- 5.23 Orion Genomics LLC Company Overview 51
- 5.23.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 51
- 5.24 PleX Diagnostics Inc (Inactive) Company Overview 52
- 5.24.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
- 5.25 ProMIS Neurosciences Inc Company Overview 53
- 5.25.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 53
- 5.26 Proplex Technologies Llc Company Overview 54
- 5.26.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 54
- 5.27 Proteome Sciences Plc Company Overview 55
- 5.27.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 55
- 5.28 Roche Diagnostics International Ltd Company Overview 56
- 5.28.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 56
- 5.29 University of Louisville Company Overview 57
- 5.29.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 57
- 5.30 University of Rochester Company Overview 58
- 5.30.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 58
- 5.31 Ventana Medical Systems Inc Company Overview 59
- 5.31.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 59
- 5.32 Viomics Inc. Company Overview 60
- 5.32.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
- 5.33 XEPTAGEN SpA Company Overview 61
- 5.33.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 61
- 5.34 Ymir Genomics LLC. Company Overview 65
- 5.34.1 Ymir Genomics LLC. Pipeline Products & Ongoing Clinical Trials Overview 65
6 Liver Cancer Diagnostic Tests - Recent Developments 66
- 6.1 Nov 05, 2019: Blueprint Medicines outlines precision therapy research vision, provides update on discovery and clinical-stage portfolio at R&D Day and reports third quarter 2019 financial results 66
- 6.2 Oct 31, 2019: Proteome Sciences: Trading update and announcement of Board Changes 68
- 6.3 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 69
- 6.4 Oct 29, 2019: Pfizer reports third-quarter 2019 results 70
- 6.5 Sep 27, 2019: Ian Read to retire as executive chairman of Pfizer’s board of directors; chief executive Officer Dr. Albert Bourla named chairman 77
- 6.6 Sep 05, 2019: Simple CEUS Scan helps diagnose Liver Cancer when MRI is uncertain 78
- 6.7 Aug 27, 2019: ProMIS Neurosciences appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board 79
7 Appendix 129
- 7.1 Methodology 129
- 7.2 About GlobalData 132
- 7.3 Contact Us 132
Summary:
Get latest Market Research Reports on Liver Cancer Diagnostic Tests. Industry analysis & Market Report on Liver Cancer Diagnostic Tests is a syndicated market report, published as Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019. It is complete Research Study and Industry Analysis of Liver Cancer Diagnostic Tests market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
